4//SEC Filing
Hove Anders D 4
Accession 0000950170-25-074459
CIK 0001637715other
Filed
May 18, 8:00 PM ET
Accepted
May 19, 4:43 PM ET
Size
10.8 KB
Accession
0000950170-25-074459
Insider Transaction Report
Form 4
Hove Anders D
10% Owner
Transactions
- Purchase
Common Stock
2025-05-15$1.85/sh+1,129,730$2,090,001→ 1,129,730 total(indirect: By Acorn Bioventures 2, L.P.) - Purchase
Common Stock
2025-05-15$1.85/sh+270,270$500,000→ 1,709,944 total
ACORN CAPITAL ADVISORS GP, LLC
10% Owner
Transactions
- Purchase
Common Stock
2025-05-15$1.85/sh+270,270$500,000→ 1,709,944 total - Purchase
Common Stock
2025-05-15$1.85/sh+1,129,730$2,090,001→ 1,129,730 total(indirect: By Acorn Bioventures 2, L.P.)
ACORN BIOVENTURES, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2025-05-15$1.85/sh+270,270$500,000→ 1,709,944 total - Purchase
Common Stock
2025-05-15$1.85/sh+1,129,730$2,090,001→ 1,129,730 total(indirect: By Acorn Bioventures 2, L.P.)
Footnotes (2)
- [F1]Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F2]Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
OnKure Therapeutics, Inc.
CIK 0001637715
Entity typeother
Related Parties
1- filerCIK 0001365618
Filing Metadata
- Form type
- 4
- Filed
- May 18, 8:00 PM ET
- Accepted
- May 19, 4:43 PM ET
- Size
- 10.8 KB